142 related articles for article (PubMed ID: 35319153)
1. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30
Gosmann J; Stadler R
J Dtsch Dermatol Ges; 2022 Apr; 20(4):514-517. PubMed ID: 35319153
[No Abstract] [Full Text] [Related]
2. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.
Henderson Berg MH; Davison K; Popradi G
Br J Dermatol; 2022 Feb; 186(2):379-381. PubMed ID: 34608632
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
11. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
12. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
13. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
14. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL; Salles G; Moskowitz AJ; Santoro A; Mehta A; Barr PM; Mehta-Shah N; Collins GP; Ansell SM; Brody JD; Domingo-Domenech E; Johnson NA; Cunningham D; Ferrari S; Lisano J; Krajewski J; Wen R; Akyol A; Crowe R; Savage KJ
Blood Adv; 2024 May; 8(10):2400-2404. PubMed ID: 38531062
[No Abstract] [Full Text] [Related]
15. Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma.
Stranzenbach R; Stadler R
J Dtsch Dermatol Ges; 2021 Mar; 19(3):383-387. PubMed ID: 33617153
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
[TBL] [Abstract][Full Text] [Related]
17. QuPath Analysis for CD30+ Cutaneous T-Cell Lymphoma.
Cieslak C; Mitteldorf C; Krömer-Olbrisch T; Kempf W; Stadler R
Am J Dermatopathol; 2023 Feb; 45(2):93-98. PubMed ID: 36669072
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma.
Podkonjak T; Cranmer H; Scarisbrick J; McCarthy G; Lilley C; Cheng LI
J Comp Eff Res; 2022 Feb; 11(3):193-202. PubMed ID: 34879742
[No Abstract] [Full Text] [Related]
20. Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series.
Arroyo-Andrés J; Agud-Dios M; Rubio-Muniz CA; Postigo C; Cortijo-Cascajares S; Ortiz-Romero PL
Int J Dermatol; 2024 Feb; 63(2):e57-e59. PubMed ID: 38093412
[No Abstract] [Full Text] [Related]
[Next] [New Search]
